Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2019

26.09.2018 | Review

Physician attitudes about cost consciousness for breast cancer treatment: differences by cancer sub-specialty

verfasst von: Ken Resnicow, Minal R. Patel, M. Chandler Mcleod, Steven J. Katz, Reshma Jagsi

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

High costs of cancer care place considerable burden on patients and society. Despite increasing recognition that providers should play a role in reducing care costs, how physicians across cancer specialties differ in their cost-consciousness has not been reported. We examined cost-consciousness regarding breast cancer care among medical oncologists, surgeons, and radiation oncologists.

Methods

We identified 514 cancer surgeons, 504 medical oncologists, and 251 radiation oncologists by patient report through the iCanCare study. iCanCare identified newly diagnosed women with breast cancer through the Surveillance, Epidemiology, and End Results (SEER) registries of Georgia and Los Angeles. We queried providers on three dimensions of cost-consciousness: (1) perceived importance of cost saving for society, patients, practice, and payers; (2) awareness of patient out-of-pocket expenses; and (3) discussion of financial burden.

Results

We received responses from 376 surgeons (73%), 304 medical oncologists (60%), and 169 radiation oncologists (67%). Overall levels of cost-consciousness were moderate, with scores ranging from 2.5 to 3.0 out of 5. After adjusting for covariates, surgeons had the lowest scores on all three cost-consciousness measures; medical oncologists had the highest scores. Pairwise contrasts showed surgeons had significantly lower scores than medical oncologists for all three measures and significantly lower scores than radiation oncologists for two of the three cost-consciousness variables: importance of cost saving and discussion of financial burden.

Conclusions

How cost-consciousness impacts medical decision-making across specialty and how policy, structural, and behavioral interventions might sensitize providers regarding cost-related matters merit further examination.
Literatur
1.
Zurück zum Zitat Institute of Medicine (2013) Delivering high-quality cancer care: charting a new course for a system in crisis. Institute of Medicine, Washington, DC Institute of Medicine (2013) Delivering high-quality cancer care: charting a new course for a system in crisis. Institute of Medicine, Washington, DC
3.
Zurück zum Zitat Carrera PM, Kantarjian HM, Blinder VS (2018) The financial burden and distress of patients with cancer: Understanding and stepping-up action on the financial toxicity of cancer treatment. CA Cancer J Clin Carrera PM, Kantarjian HM, Blinder VS (2018) The financial burden and distress of patients with cancer: Understanding and stepping-up action on the financial toxicity of cancer treatment. CA Cancer J Clin
5.
Zurück zum Zitat Zafar SY, Abernethy AP (2013) Financial toxicity, Part I: a new name for a growing problem. Oncology (Williston Park) 27(2):80–81, 149 Zafar SY, Abernethy AP (2013) Financial toxicity, Part I: a new name for a growing problem. Oncology (Williston Park) 27(2):80–81, 149
6.
Zurück zum Zitat Ryskina KL, Halpern SD, Minyanou NS, Goold SD, Tilburt JC (2015) The role of training environment care intensity in US physician cost consciousness. Mayo Clinic Proc 90(3):313–320CrossRef Ryskina KL, Halpern SD, Minyanou NS, Goold SD, Tilburt JC (2015) The role of training environment care intensity in US physician cost consciousness. Mayo Clinic Proc 90(3):313–320CrossRef
7.
Zurück zum Zitat Grover M, Abraham N, Chang YH, Tilburt J (2016) Physician cost consciousness and use of low-value clinical services. J Am Board Fam Med 29(6):785–792CrossRefPubMed Grover M, Abraham N, Chang YH, Tilburt J (2016) Physician cost consciousness and use of low-value clinical services. J Am Board Fam Med 29(6):785–792CrossRefPubMed
8.
Zurück zum Zitat Ramsey SD, Bansal A, Fedorenko CR, Blough DK, Overstreet KA, Shankaran V, Newcomb P (2016) Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer. J Clin Oncol 34(9):980CrossRefPubMedPubMedCentral Ramsey SD, Bansal A, Fedorenko CR, Blough DK, Overstreet KA, Shankaran V, Newcomb P (2016) Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer. J Clin Oncol 34(9):980CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Workman PDG, Schellens JHM, Bernards R (2017) How Much Longer Will We Put Up With $100,000 Cancer Drugs? Cell 168(4):579–583CrossRefPubMed Workman PDG, Schellens JHM, Bernards R (2017) How Much Longer Will We Put Up With $100,000 Cancer Drugs? Cell 168(4):579–583CrossRefPubMed
10.
Zurück zum Zitat Tilburt JC, Wynia MK, Sheeler RD, Thorsteinsdottir B, James KM, Egginton JS, Liebow M, Hurst S, Danis M, Goold SD (2013) Views of US physicians about controlling health care costs. Jama 310(4):380–388CrossRefPubMedPubMedCentral Tilburt JC, Wynia MK, Sheeler RD, Thorsteinsdottir B, James KM, Egginton JS, Liebow M, Hurst S, Danis M, Goold SD (2013) Views of US physicians about controlling health care costs. Jama 310(4):380–388CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Neumann PJ, Palmer JA, Nadler E, Fang C, Ubel P (2010) Cancer therapy costs influence treatment: A national survey of oncologists. Health Affairs (Project Hope) 29(1):196–202CrossRef Neumann PJ, Palmer JA, Nadler E, Fang C, Ubel P (2010) Cancer therapy costs influence treatment: A national survey of oncologists. Health Affairs (Project Hope) 29(1):196–202CrossRef
12.
Zurück zum Zitat Schrag D, Hanger M (2007) Medical oncologists’ views on communicating with patients about chemotherapy costs: a pilot survey. J Clin Oncol 25(2):233–237CrossRefPubMed Schrag D, Hanger M (2007) Medical oncologists’ views on communicating with patients about chemotherapy costs: a pilot survey. J Clin Oncol 25(2):233–237CrossRefPubMed
13.
Zurück zum Zitat Berry SR, Bell CM, Ubel PA, Evans WK, Nadler E, Strevel EL, Neumann PJ (2010) Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs. J Clin Oncol 28(27):4149–4153CrossRefPubMed Berry SR, Bell CM, Ubel PA, Evans WK, Nadler E, Strevel EL, Neumann PJ (2010) Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs. J Clin Oncol 28(27):4149–4153CrossRefPubMed
14.
Zurück zum Zitat Nadler E, Eckert B, Neumann PJ (2006) Do oncologists believe new cancer drugs offer good value? Oncologist 11(2):90–95CrossRefPubMed Nadler E, Eckert B, Neumann PJ (2006) Do oncologists believe new cancer drugs offer good value? Oncologist 11(2):90–95CrossRefPubMed
15.
Zurück zum Zitat Morrow M, Abrahamse P, Hofer TP, Ward KC, Hamilton AS, Kurian AW, Katz SJ, Jagsi R (2017) Trends in reoperation after initial lumpectomy for breast cancer: addressing overtreatment in surgical management. JAMA Oncol 3(10):1352–1357CrossRefPubMedPubMedCentral Morrow M, Abrahamse P, Hofer TP, Ward KC, Hamilton AS, Kurian AW, Katz SJ, Jagsi R (2017) Trends in reoperation after initial lumpectomy for breast cancer: addressing overtreatment in surgical management. JAMA Oncol 3(10):1352–1357CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Katz SJ, Hawley ST, Bondarenko I, Jagsi R, Ward KC, Hofer TP, Kurian AW (2017) Oncologists’ influence on receipt of adjuvant chemotherapy: does it matter whom you see for treatment of curable breast cancer? Breast Cancer Res Treat 165(3):751–756CrossRefPubMedPubMedCentral Katz SJ, Hawley ST, Bondarenko I, Jagsi R, Ward KC, Hofer TP, Kurian AW (2017) Oncologists’ influence on receipt of adjuvant chemotherapy: does it matter whom you see for treatment of curable breast cancer? Breast Cancer Res Treat 165(3):751–756CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Katz SJ, Hawley ST, Hamilton AS, Ward KC, Morrow M, Jagsi R, Hofer TP (2018) Surgeon influence on variation in receipt of contralateral prophylactic mastectomy for women with breast cancer. JAMA Surg 153(1):29–36CrossRefPubMed Katz SJ, Hawley ST, Hamilton AS, Ward KC, Morrow M, Jagsi R, Hofer TP (2018) Surgeon influence on variation in receipt of contralateral prophylactic mastectomy for women with breast cancer. JAMA Surg 153(1):29–36CrossRefPubMed
18.
Zurück zum Zitat Dillman DSJ, Christian L (2009) Internet, mail, and mixed-mode surveys: the tailored design method, 3rd edn. Wiley, Hoboken Dillman DSJ, Christian L (2009) Internet, mail, and mixed-mode surveys: the tailored design method, 3rd edn. Wiley, Hoboken
19.
Zurück zum Zitat Goold SD, Hofer T, Zimmerman M, Hayward RA (1994) Measuring physician attitudes toward cost, uncertainty, malpractice, and utilization review. J Gen Intern Med 9(10):544–549CrossRefPubMed Goold SD, Hofer T, Zimmerman M, Hayward RA (1994) Measuring physician attitudes toward cost, uncertainty, malpractice, and utilization review. J Gen Intern Med 9(10):544–549CrossRefPubMed
20.
Zurück zum Zitat Cooke M (2010) Cost consciousness in patient care–what is medical education’s responsibility? N Engl J Med 362(14):1253–1255CrossRefPubMed Cooke M (2010) Cost consciousness in patient care–what is medical education’s responsibility? N Engl J Med 362(14):1253–1255CrossRefPubMed
21.
Zurück zum Zitat Collins SR, Gunja MZ, Doty MM (2017) Following the ACA repeal-and-replace effort, where does the U.S. stand on insurance coverage? Findings from the commonwealth fund affordable care act tracking survey. Issue Brief (Commonw Fund) 2017:1–21 Collins SR, Gunja MZ, Doty MM (2017) Following the ACA repeal-and-replace effort, where does the U.S. stand on insurance coverage? Findings from the commonwealth fund affordable care act tracking survey. Issue Brief (Commonw Fund) 2017:1–21
Metadaten
Titel
Physician attitudes about cost consciousness for breast cancer treatment: differences by cancer sub-specialty
verfasst von
Ken Resnicow
Minal R. Patel
M. Chandler Mcleod
Steven J. Katz
Reshma Jagsi
Publikationsdatum
26.09.2018
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2019
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-018-4976-7

Weitere Artikel der Ausgabe 1/2019

Breast Cancer Research and Treatment 1/2019 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.